1887

Abstract

Rhesus cytomegalovirus (RhCMV) exhibits strong parallels with human CMV (HCMV) in terms of nucleic and amino acid identities, natural history, and mechanisms of persistence and pathogenesis in its natural host, rhesus macaques (). To determine whether this non-human primate model would be useful to assess vaccine strategies for HCMV, host immune responses to RhCMV glycoprotein B (gB) were evaluated in RhCMV-infected monkeys. Total protein extracts were prepared from cells transiently transfected with an expression plasmid for either the full-length gB or a derivative (gBΔ, 1–680 aa) lacking both the transmembrane domain and cytoplasmic tail. Western blot analysis showed identical reactivity of macaque sera with full-length gB and its derivative gBΔ, indicating that the immunodominant epitopes of gB are contained in the extracellular portion of the protein. Using gBΔ extract as a solid phase, a sensitive and specific ELISA was established to characterize gB antibody responses in monkeys acutely and chronically infected with RhCMV. During primary infection (seroconversion), gB-specific antibodies developed concurrently and in parallel with total RhCMV-specific antibodies. However, during chronic infection gB-specific antibody responses were variable. A strong correlation was observed between neutralizing and gB-specific antibody levels in RhCMV-seropositive monkeys. Taken together, the results of this study indicate that, similar to host humoral responses to HCMV gB, anti-gB antibodies are an integral part of humoral immunity to RhCMV infection and probably play an important protective role in limiting the extent of RhCMV infection. Thus, the rhesus macaque model of HCMV infection is relevant for testing gB-based immune therapies.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.19508-0
2003-12-01
2020-07-02
Loading full text...

Full text loading...

/deliver/fulltext/jgv/84/12/vir843371.html?itemId=/content/journal/jgv/10.1099/vir.0.19508-0&mimeType=html&fmt=ahah

References

  1. Alberola J., Dominguez V., Cardenoso L.. 7 other authors 1998; Antibody response to human cytomegalovirus (HCMV) glycoprotein B (gB) in AIDS patients with HCMV end-organ disease. J Med Virol55:272–280
    [Google Scholar]
  2. Alberola J., Tamarit A., Cardenoso L., Estelles F., Igual R., Navarro D.. 2001; Longitudinal analysis of human cytomegalovirus glycoprotein B (gB)-specific and neutralizing antibodies in AIDS patients either with or without cytomegalovirus end-organ disease. J Med Virol64:35–41
    [Google Scholar]
  3. Alcendor D. J., Barry P. A., Pratt-Lowe E., Luciw P. A.. 1993; Analysis of the rhesus cytomegalovirus immediate-early gene promoter. Virology194:815–821
    [Google Scholar]
  4. Alford C. A., Britt W. J.. 1993; Cytomegalovirus. In The Human Herpesviruses pp 227–255 Edited by Roizman B., Whitley R. J., Lopez C.. New York: Raven Press;
    [Google Scholar]
  5. Asher D. M., Gibbs J., J C, Lang D. J., Gadjusek D. C., Chanock R. M.. 1974; Persistent shedding of cytomegalovirus in the urine of healthy rhesus monkeys. Proc Soc Exp Biol Med145:794–801
    [Google Scholar]
  6. Baroncelli S., Barry P. A., Capitanio J. P., Lerche N. W., Otsyula M., Mendoza S. P.. 1997; Cytomegalovirus and simian immunodeficiency virus coinfection: longitudinal study of antibody responses and disease progression. J Acquir Immune Defic Syndr15:5–15
    [Google Scholar]
  7. Baskin G. B.. 1987; Disseminated cytomegalovirus infection in immunodeficient rhesus macaques. Am J Pathol129:345–352
    [Google Scholar]
  8. Boppana S. B., Britt W. J.. 1995; Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis171:1115–1121
    [Google Scholar]
  9. Boppana S. B., Britt W. J.. 1996; Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells. Virology222:293–296
    [Google Scholar]
  10. Britt W. J., Auger D.. 1985; Identification of a 65 000 dalton virion envelope protein of human cytomegalovirus. Virus Res4:31–36
    [Google Scholar]
  11. Britt W. J., Mach M.. 1996; Human cytomegalovirus glycoproteins. Intervirology39:401–412
    [Google Scholar]
  12. Britt W. J., Vugler L., Butfiloski E. J., Stephens E. B.. 1990; Cell surface expression of human cytomegalovirus (HCMV) gp55–116 (gB): use of HCMV-vaccinia recombinant virus-infected cells in analysis of the human neutralizing response. J Virol64:1079–1085
    [Google Scholar]
  13. Chang W. L., Barry P. A.. 2003; Cloning of the full-length rhesus cytomegalovirus genome as an infectious and self-excisable bacterial artificial chromosome for analysis of viral pathogenesis. J Virol77:5073–5083
    [Google Scholar]
  14. Chang W. L., Tarantal A. F., Zhou S. S., Borowsky A. D., Barry P. A.. 2002; A recombinant rhesus cytomegalovirus expressing enhanced green fluorescent protein retains the wild-type phenotype and pathogenicity in fetal macaques. J Virol76:9493–9504
    [Google Scholar]
  15. Chee M. S., Bankier A. T., Beck S.. 12 other authors 1990; Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Topics Microbiol Immunol154:125–169
    [Google Scholar]
  16. Davison A. J., Dolan A., Akter P., Addison C., Dargan D. J., Alcendor D. J., McGeoch D. J., Hayward G. S.. 2003; The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome. J Gen Virol84:17–28
    [Google Scholar]
  17. DuBridge R. B., Tang P., Hsia H. C., Leong P. M., Miller J. H., Calos M. P.. 1987; Analysis of mutation in human cells by using an Epstein–Barr virus shuttle system. Mol Cell Biol7:379–387
    [Google Scholar]
  18. Fowler K. B., Stagno S., Pass R. F., Britt W. J., Boll T. J., Alford C. A.. 1992; The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med326:663–667
    [Google Scholar]
  19. Gibson W.. 1983; Protein counterparts of human and simian cytomegaloviruses. Virol128:391–406
    [Google Scholar]
  20. Gonczol E., Ianacone J., Ho W. Z., Starr S., Meignier B., Plotkin S.. 1990; Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers. Vaccine8:130–136
    [Google Scholar]
  21. Hansen S. G., Strelow L. I., Franchi D. C., Anders D. G., Wong S. W.. 2003; Complete sequence and genomic analysis of rhesus cytomegalovirus. J Virol77:6620–6636
    [Google Scholar]
  22. Hopkins J. I., Fiander A. N., Evans A. S., Delchambre M., Gheysen D., Borysiewicz L. K.. 1996; Cytotoxic T cell immunity to human cytomegalovirus glycoprotein B. J Med Virol49:124–131
    [Google Scholar]
  23. Huff J. L., Eberle R., Capitanio J., Zhou S. S., Barry P. A.. 2003; Differential detection of B virus and rhesus cytomegalovirus in rhesus macaques. J Gen Virol84:83–92
    [Google Scholar]
  24. Jonjic S., Pavic I., Polic B., Crnkovic I., Lucin P., Koszinowski U. H.. 1994; Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J Exp Med179:1713–1717
    [Google Scholar]
  25. Kaur A., Daniel M. D., Hempel D., Lee-Parritz D., Hirsch M. S., Johnson R. P.. 1996; Cytotoxic T-lymphocyte responses to cytomegalovirus in normal and simian immunodeficiency virus-infected macaques. J Virol70:7725–7733
    [Google Scholar]
  26. Kaur A., Grant R. M., Means R. E., McClure H., Feinberg M., Johnson R. P.. 1998; Diverse host responses and outcomes following simian immunodeficiency virus SIVmac239 infection in sooty mangabeys and rhesus macaques. J Virol72:9597–9611
    [Google Scholar]
  27. Kaur A., Hale C. L., Noren B., Kassis N., Simon M. A., Johnson R. P.. 2002; Decreased frequency of cytomegalovirus (CMV)-specific CD4+ T lymphocytes in simian immunodeficiency virus-infected rhesus macaques: inverse relationship with CMV viremia. J Virol76:3646–3658
    [Google Scholar]
  28. Kravitz R. H., Sciabica K. S., Cho K., Luciw P. A., Barry P. A.. 1997; Cloning and characterization of the rhesus cytomegalovirus glycoprotein B. J Gen Virol78:2009–2013
    [Google Scholar]
  29. Kropff B., Mach M.. 1997; Identification of the gene coding for rhesus cytomegalovirus glycoprotein B and immunological analysis of the protein. J Gen Virol78:1999–2007
    [Google Scholar]
  30. Kuhn E. M., Stolte N., Matz-Rensing K., Mach M., Stahl-Henning C., Hunsmann G., Kaup F. J.. 1999; Immunohistochemical studies of productive rhesus cytomegalovirus infection in rhesus monkeys ( Macaca mulatta ) infected with simian immunodeficiency virus. Vet Pathol36:51–56
    [Google Scholar]
  31. Li C. R., Greenberg P. D., Gilbert M. J., Goodrich J. M., Riddell S. R.. 1994; Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood83:1971–1979
    [Google Scholar]
  32. Liu Y. N., Klaus A., Kari B., Stinski M. F., Eckhardt J., Gehrz R. C.. 1991; The N-terminal 513 amino acids of the envelope glycoprotein gB of human cytomegalovirus stimulates both B- and T-cell immune responses in humans. J Virol65:1644–1648
    [Google Scholar]
  33. Lockridge K. M., Sequar G., Zhou S. S., Yue Y., Mandell C. M., Barry P. A.. 1999; Pathogenesis of experimental rhesus cytomegalovirus infection. J Virol73:9576–9583
    [Google Scholar]
  34. Loomis-Huff J. E., Eberle R., Lockridge K. M., Rhodes G., Barry P. A.. 2001; Immunogenicity of a DNA vaccine against herpes B virus in mice and rhesus macaques. Vaccine19:4865–4873
    [Google Scholar]
  35. Marshall G. S., Rabalais G. P., Stout G. G., Waldeyer S. L.. 1992; Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J Infect Dis165:381–384
    [Google Scholar]
  36. Marshall G. S., Stout G. G., Knights M. E., Rabalais G. P., Ashley R., Miller H., Rossier E.. 1994; Ontogeny of glycoprotein gB-specific antibody and neutralizing activity during natural cytomegalovirus infection. J Med Virol43:77–83
    [Google Scholar]
  37. Marshall G. S., Fenger D. P., Stout G. G., Knights M. E., Hunt L. A.. 1996; Processing of human cytomegalovirus glycoprotein B in recombinant adenovirus-infected cells. J Gen Virol77:1549–1557
    [Google Scholar]
  38. Marshall G. S., Li M., Stout G. G., Louthan M. V., Duliege A. M., Burke R. L., Hunt L. A.. 2000; Antibodies to the major linear neutralizing domains of cytomegalovirus glycoprotein B among natural seropositives and CMV subunit vaccine recipients. Viral Immunol13:329–341
    [Google Scholar]
  39. Navarro D., Lennette E., Tugizov S., Pereira L.. 1997; Humoral immune response to functional regions of human cytomegalovirus glycoprotein B. J Med Virol52:451–459
    [Google Scholar]
  40. Pitcher C. J., Hagen S. I., Walker J. M., Lum R., Mitchell B. L., Maino V. C., Axthelm M. K., Picker L. J.. 2002; Development and homeostasis of T cell memory in rhesus macaque. J Immunol168:29–43
    [Google Scholar]
  41. Polic B., Hengel H., Krmpotic A., Trgovcich J., Pavic I., Luccaronin P., Jonjic S., Koszinowski U. H.. 1998; Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med188:1047–1054
    [Google Scholar]
  42. Qadri I., Navarro D., Paz P., Pereira L.. 1992; Assembly of conformation-dependent neutralizing domains on glycoprotein B of human cytomegalovirus. J Gen Virol73:2913–2921
    [Google Scholar]
  43. Rasmussen L., Morris S., Zipeto D., Fessel J., Wolitz R., Dowling A., Merigan T. C.. 1995; Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. J Infect Dis171:177–182
    [Google Scholar]
  44. Reddehase M. J., Mutter W., Münch K., Bühring H.-J., Koszinowski U. H.. 1987; CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol61:3102–3108
    [Google Scholar]
  45. Reusser P., Riddell S. R., Meyers J. D., Greenberg P. D.. 1991; Cytotoxic T-lymphocyte response to cytomegalovirus after human alogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood78:1373–1380
    [Google Scholar]
  46. Reusser P., Attenhofer R., Hebart H., Helg C., Chapuis B., Einsele H.. 1997; Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants. Blood89:3873–3879
    [Google Scholar]
  47. Reusser P., Cathomas G., Attenhofer R., Tamm M., Thiel G.. 1999; Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J Infect Dis180:247–253
    [Google Scholar]
  48. Riddell S. R., Watanabe K. S., Goodrich J. M., Li C. R., Agha M. E., Greenberg P. D.. 1992; Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science257:238–241
    [Google Scholar]
  49. Rigoutsos I., Novotny J., Huynh T., Chin-Bow S. T., Parida L., Platt D., Coleman D., Shenk T.. 2003; In silico pattern-based analysis of the human cytomegalovirus genome. J Virol77:4326–4344
    [Google Scholar]
  50. Schoppel K., Kropff B., Schmidt C., Vornhagen R., Mach M.. 1997; The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies. J Infect Dis175:533–544
    [Google Scholar]
  51. Schoppel K., Schmidt C., Einsele H., Hebart H., Mach M.. 1998; Kinetics of the antibody response against human cytomegalovirus- specific proteins in allogeneic bone marrow transplant recipients. J Infect Dis178:1233–1243
    [Google Scholar]
  52. Sequar G., Britt W. J., Lakeman F. D., Lockridge K. M., Tarara R. P., Canfield D. R., Zhou S. S., Gardner M. B., Barry P. A.. 2002; Experimental coinfection of rhesus macaques with rhesus cytomegalovirus and simian immunodeficiency virus: pathogenesis. J Virol76:7661–7671
    [Google Scholar]
  53. Spaete R. R., Thayer R. M., Probert W. S., Masiarz F. R., Chamberlain S. H., Rasmussen L., Merigan T. C., Pachl C.. 1988; Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. Virology 167:207–225
    [Google Scholar]
  54. Swack N. S., Hsiung G. D.. 1982; Natural and experimental simian cytomegalovirus infections at a primate center. J Med Primatol 11:169–177
    [Google Scholar]
  55. Urban M., Klein M., Britt W. J., Hassfurther E., Mach M.. 1996; Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol77:1537–1547
    [Google Scholar]
  56. Utz U., Britt W., Vugler L., Mach M.. 1989; Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. J Virol63:1995–2001
    [Google Scholar]
  57. Vogel P., Weigler B. J., Kerr H., Hendrickx A., Barry P. A.. 1994; Seroepidemiologic studies of cytomegalovirus infection in a breeding population of rhesus macaques. Lab Anim Sci44:25–30
    [Google Scholar]
  58. Walter E. A., Greenberg P. D., Gilbert M. J., Finch R. J., Watanabe K. S., Thomas E. D., Riddell S. R.. 1995; Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med333:1038–1044
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.19508-0
Loading
/content/journal/jgv/10.1099/vir.0.19508-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error